Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
The possible treatments options for metastatic hormone-sensitive prostate cancer (mHSPC) have dramatically increased during the last years. The old backbone, which androgen-deprivation therapy (ADT) is the exclusive approach for hormone-naïve patients, has been disrupted. Despite the fact t...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/11/9/1355 |
| _version_ | 1797721047172120576 |
|---|---|
| author | Carlo Cattrini Elena Castro Rebeca Lozano Elisa Zanardi Alessandra Rubagotti Francesco Boccardo David Olmos |
| author_facet | Carlo Cattrini Elena Castro Rebeca Lozano Elisa Zanardi Alessandra Rubagotti Francesco Boccardo David Olmos |
| author_sort | Carlo Cattrini |
| collection | DOAJ |
| description | The possible treatments options for metastatic hormone-sensitive prostate cancer (mHSPC) have dramatically increased during the last years. The old backbone, which androgen-deprivation therapy (ADT) is the exclusive approach for hormone-naïve patients, has been disrupted. Despite the fact that several high-quality, randomized, controlled phase 3 trials have been conducted in this setting, no direct comparison is currently available among the different strategies. Inadequate power, absence of preplanning and small sample size frequently affect the subgroup analyses according to disease volume or patient’s risk. The choice between ADT alone and ADT combined with docetaxel, abiraterone acetate, enzalutamide, apalutamide or radiotherapy to the primary tumor remains challenging. Factors that are related to the tumor, patient or drug side effects, currently guide these clinical decisions. This comprehensive review aims to indirectly compare the phase 3 trials in the mHSPC setting, in order to extrapolate data useful for treatment selection, providing also perspectives on future biomarkers. |
| first_indexed | 2024-03-12T09:28:09Z |
| format | Article |
| id | doaj.art-48b10c9dfa324198af57965c4da0bb10 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T09:28:09Z |
| publishDate | 2019-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-48b10c9dfa324198af57965c4da0bb102023-09-02T14:02:07ZengMDPI AGCancers2072-66942019-09-01119135510.3390/cancers11091355cancers11091355Current Treatment Options for Metastatic Hormone-Sensitive Prostate CancerCarlo Cattrini0Elena Castro1Rebeca Lozano2Elisa Zanardi3Alessandra Rubagotti4Francesco Boccardo5David Olmos6Academic Unit of Medical Oncology, IRCCS San Martino Polyclinic Hospital, 16132 Genoa, ItalyProstate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, SpainProstate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, SpainAcademic Unit of Medical Oncology, IRCCS San Martino Polyclinic Hospital, 16132 Genoa, ItalyAcademic Unit of Medical Oncology, IRCCS San Martino Polyclinic Hospital, 16132 Genoa, ItalyAcademic Unit of Medical Oncology, IRCCS San Martino Polyclinic Hospital, 16132 Genoa, ItalyProstate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, SpainThe possible treatments options for metastatic hormone-sensitive prostate cancer (mHSPC) have dramatically increased during the last years. The old backbone, which androgen-deprivation therapy (ADT) is the exclusive approach for hormone-naïve patients, has been disrupted. Despite the fact that several high-quality, randomized, controlled phase 3 trials have been conducted in this setting, no direct comparison is currently available among the different strategies. Inadequate power, absence of preplanning and small sample size frequently affect the subgroup analyses according to disease volume or patient’s risk. The choice between ADT alone and ADT combined with docetaxel, abiraterone acetate, enzalutamide, apalutamide or radiotherapy to the primary tumor remains challenging. Factors that are related to the tumor, patient or drug side effects, currently guide these clinical decisions. This comprehensive review aims to indirectly compare the phase 3 trials in the mHSPC setting, in order to extrapolate data useful for treatment selection, providing also perspectives on future biomarkers.https://www.mdpi.com/2072-6694/11/9/1355hormone-sensitive prostate cancerhormone-naïve prostate cancerdocetaxelenzalutamideabiraterone acetateapalutamideradiotherapy |
| spellingShingle | Carlo Cattrini Elena Castro Rebeca Lozano Elisa Zanardi Alessandra Rubagotti Francesco Boccardo David Olmos Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer Cancers hormone-sensitive prostate cancer hormone-naïve prostate cancer docetaxel enzalutamide abiraterone acetate apalutamide radiotherapy |
| title | Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer |
| title_full | Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer |
| title_fullStr | Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer |
| title_full_unstemmed | Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer |
| title_short | Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer |
| title_sort | current treatment options for metastatic hormone sensitive prostate cancer |
| topic | hormone-sensitive prostate cancer hormone-naïve prostate cancer docetaxel enzalutamide abiraterone acetate apalutamide radiotherapy |
| url | https://www.mdpi.com/2072-6694/11/9/1355 |
| work_keys_str_mv | AT carlocattrini currenttreatmentoptionsformetastatichormonesensitiveprostatecancer AT elenacastro currenttreatmentoptionsformetastatichormonesensitiveprostatecancer AT rebecalozano currenttreatmentoptionsformetastatichormonesensitiveprostatecancer AT elisazanardi currenttreatmentoptionsformetastatichormonesensitiveprostatecancer AT alessandrarubagotti currenttreatmentoptionsformetastatichormonesensitiveprostatecancer AT francescoboccardo currenttreatmentoptionsformetastatichormonesensitiveprostatecancer AT davidolmos currenttreatmentoptionsformetastatichormonesensitiveprostatecancer |